Daiichi Sankyo subsidiary Luitpold Pharmaceuticals has acquired Roxro Pharma, which specializes in intranasal delivery of analgesics. Roxro’s lead product is Sprix ketorolac tromethamine nasal spray for short-term pain management. Sprix received FDA approval in May 2010 but has not yet been marketed. Read the company’s press release.
